Acute Respiratory Distress Syndrome Global Clinical Trials Review, H1, 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Acute Respiratory Distress Syndrome Global Clinical Trials Review, H1, 2016" clinical trials to their offering.

The report provides an overview of Acute Respiratory Distress Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Respiratory Distress Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope of the Report:

  • The report provides a snapshot of the global clinical trials landscape.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status.
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment.
  • The Report provides enrollment trends for the past five years.
  • Report provides latest news for the past three months.

Reasons to buy:

  • Assists in formulating key business strategies with regards to investment.
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities.
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market.
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials.
  • Facilitates clinical trial assessment of the indication on a global, regional and country level.

Companies Mentioned:

  • GlaxoSmithKline Plc
  • Discovery Laboratories, Inc.
  • Serendex Pharmaceuticals A/S
  • Pierrel S.p.A.
  • Mallinckrodt Plc
  • Faron Pharmaceuticals Oy
  • F. Hoffmann-La Roche Ltd.
  • Altor BioScience Corporation
  • Actelion Ltd
  • Abbott Laboratories

For more information visit http://www.researchandmarkets.com/research/8mcf2q/acute_respiratory

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716